Navigation Links
Nordic Nanovector to Present at Biotech Showcase 2017
Date:1/4/2017

OSLO, Norway,, Jan 04, 2017 /PRNewswire/ --

Nordic Nanovector ASA (OSE: NANO), a biotechnology company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology, announces today that Chief Operating Officer (COO), Marco Renoldi, MD, will present at the 9th Annual Biotech Showcase™ on Monday, January 9th 2017, San Francisco, US. The investor and partnering conference attracts pharmaceutical executives from around the world focused on investment and business development opportunities in the life sciences industry.

COO, Marco Renoldi, MD, will present an overview of the company, including an introduction to Betalutin®, a potential first-in-class treatment for non-Hodgkin lymphoma, latest patient data presented at ASH in December 2016, its development strategy, key milestones and market opportunities. Mr Renoldi will also provide a summary of the company's broader development strategy based around building a pipeline of innovative targeted therapies for haematological cancers.

The presentation will take place on Monday, January 9, 2017 at 10:30-11:00 a.m. Pacific Time and the slides presented will be made available on Nordic Nanovector's website (www.nordicnanovector.com), Investor Relations/Reports and Presentations/Presentations/2017.

For further information, please contact:

IR enquiries:
Luigi Costa, Chief Executive Officer
Cell: +41 79 124 8601

Tone Kvåle,
Chief Financial Officer
Cell: +47 91 51 95 76
Email: ir@nordicnanovector.com

Media enquiries:
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 282 2948/+44 207 282 2949
Email: nordicnanovector@citigatedr.co.uk

About Nordic Nanovector:

Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company's lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019.
Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications.

Further information about the Company can be found at www.nordicnanovector.com

This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/nordic-nanovector/r/nordic-nanovector-to-present-at-biotech-showcase-2017,c2160147

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nordic-nanovector-to-present-at-biotech-showcase-2017-300385285.html


'/>"/>
SOURCE Nordic Nanovector
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. AMRA, BerGenBio et Nexstim reçoivent les prix Nordic Stars 2015 lors des NLSDays à Stockholm
2. Verleihung des Nordic Stars 2015 Awards an AMRA, BerGenBio und Nexstim auf den NLSDays in Stockholm
3. AMRA, BerGenBio and Nexstim Receive Nordic Stars 2015 Awards at NLSDays in Stockholm
4. Nordic Building Constructors Industry Report by Researchmoz
5. Intense Competition Propelling Nordic Builders Merchants Industry
6. Nordic Life Science Days - Successful International Life Science Business Meeting in the Nordic Countries
7. Enteris BioPharma and Nordic BioSciences KeyBioScience Enter Strategic Licensing Agreement to Develop Metabolic Peptides Using Enteris Proprietary Oral Drug Delivery and Manufacturing Platform
8. Greenphires ClinCard Technology Platform selected by Bavarian Nordic for Major Vaccine Trial
9. WuXi NextCODE to Present at the 35th Annual JP Morgan Healthcare Conference
10. VolitionRx Limited to Present at 9th Annual Biotech Showcase Conference
11. Ehave to Present at the Digital Medicine Showcase 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... Dr. Bob ... at his local San Diego Rotary Club. The event entitled “Stem ... CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon ... awards honoring scientists who have made outstanding contributions to analytical chemistry ... Pittcon 2018, the world’s leading conference and exposition for laboratory science, which will ...
Breaking Biology Technology:
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
Breaking Biology News(10 mins):